Exhibit 99.1

  

 

DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2015 Financial Results and Provides Corporate Update

 

- Lead product candidate, VAL-083 for the treatment of glioblastoma multiforme (GBM), positioned to enter registration-directed Phase II/III clinical trials in 2H 2015 -

 

VANCOUVER, British Columbia and MENLO PARK, Calif., May 18, 2015 /PRNewswire/

-- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced its financial results for the three and nine months ending March 31, 2015 and provided an overview of recent Company highlights and expected near-term milestones.

 

RECENT HIGHLIGHTS

 

VAL-083 (dianhydrogalactitol), for the treatment of glioblastoma multiforme (GBM)

Announced completion of dose-escalation in VAL-083 Phase I/II clinical trial and initiation of activities to prepare for advancement to registration-directed Phase II/III clinical trials as a potential new treatment for refractory GBM, the most common and deadly form of brain cancer.
Presented new preclinical data activity of VAL-083 against temozolomide-resistant GBM as a potential therapeutic option for GBM patients who fail or are unlikely to respond to current front-line therapy; and
Added the Mayo Clinic Cancer Center in Rochester, Minn. as the fourth clinical trial site recruiting patients with recurrent malignant GBM for the Phase I/II multicenter study.

 

VAL-083 for the treatment of non-small cell lung cancer (NSCLC)

Presented preclinical data in lung cancer models supporting differentiation of VAL-083 versus platinum-based chemotherapy as a potential option to address a significant unmet need in treatment of drug-resistant NSCLC.

 

Corporate

 

Participated in a panel focused on strategies for maintaining and expanding a relevant, robust therapeutic product candidate pipeline in the rapidly changing oncology landscape at Cancer Advance Boston;
Appointed biopharmaceutical industry veteran, Erich Mohr, Ph.D., R.Psych., and accomplished health care executive, Lynda Cranston, BScN, MScN, ICD.D, to its Board of Directors as independent directors. Ms. Cranston is serving as Chair of the Company’s newly formed Governance and Compensation Committee;
Received a notice of allowance for a fourth United States patent covering methods of use and compositions for VAL-083. Upon issuance, the Company will hold four U.S. patents and one international patent for VAL-083, having filed a total of more than ten new patent applications, which are being prosecuted in the United States and in international jurisdictions.

 

“The third quarter of fiscal 2015 was marked by several key data milestones related to our 'first-in-class' small molecule chemotherapeutic, VAL-083, and its potential to address a significant unmet need as a new therapy for GBM patients who fail, or are unlikely to respond to, current standard of care. Based on recently reported pre-clinical data, we believe VAL-083 has the potential to replace temozolomide (TMZ) as the chemotherapy of choice in chemo-radiation treatment in a majority of newly diagnosed GBM patients whose tumors express features correlated with resistance to standard chemotherapy,” stated Jeffrey Bacha, president & CEO of DelMar Pharmaceuticals.

1
 

 

“We are also very pleased with the progress and potential for VAL-083 in NSCLC and believe it will be a very important therapy, especially in drug-resistant NSCLC where there are many shortcomings in the current treatments available. Our goal is to initiate new human clinical trials with VAL-083 as a potential new therapy for NSCLC this year.”

 

ANTICIPATED NEAR-TERM MILESTONES

Advance VAL-083 into open-label Phase II/III registration-directed clinical trials for refractory GBM before year end;
Present additional data in both GBM and NSCLC at upcoming peer-reviewed scientific meetings over the remainder of 2015;
Initiate clinical trials with VAL-083 in NSCLC;
Seek to implement strategies that will enable DelMar to meet the qualifications to list its shares on a national stock exchange; and
Build further upon the intellectual property portfolio for VAL-083.

 

SUMMARY OF FINANCIAL RESULTS FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2015

For the nine months ended March 31, 2015, the Company reported a net loss of approximately $4,050,000, or a net loss per share of $0.11, compared to a net income of approximately $2,730,000, or a net income per share, of $0.09 for the nine months ended March 31, 2014. The income from 2014 was due to the revaluation of our derivative liability. During the nine months ended March 31, 2015 the Company has reduced its derivative liability from approximately $3,300,000 at June 30, 2014 to approximately $1,500,000 at March 31, 2015 through warrant exercises and exchanges.

 

The Company ended the third fiscal quarter with approximately $3,000,000 of cash.

 

The Company will present its next clinical data at the 2015 American Association of Clinical Oncology (ASCO) Annual Meeting on Monday June 1, 2015. DelMar plans to hold an investor call to discuss its latest data and financial results following the ASCO meeting.

 

FINANCIAL SUMMARY

The following represents selected financial information as of March 31, 2015. The Company's financial information has been prepared in accordance with U.S. GAAP and this selected information should be read in conjunction with DelMar's financial statements and Management's Discussion and Analysis (MD&A), as filed.

 

DelMar's financial statements as filed with the U.S. Securities Exchange Commission can be viewed on the company's website at: http://ir.delmarpharma.com/all-sec-filings.

 

2
 

 

Selected Balance Sheet Data:

 

    

March 31,

2015

$

    

June 30,

2014

$

 
Cash and cash equivalents   3,006,598    4,759,711 
Working capital   2,883,603    4,704,044 
Total Assets   3,413,281    5,003,910 
Derivative liability   1,487,137    3,329,367 
Total stockholders’ equity   1,217,021    880,479 

 

Selected Statement of Quarterly Operations:

 

For the three months ended:
  

March 31,

2015

$

  

March 31,

2014

$

 
Research and development   641,839    618,869 
General and administrative   500,753    966,923 
Change in fair value of derivative liability   343,569    1,599,349 
Loss on exchange of warrants   156,219    - 
Foreign exchange loss   6,826    11,947 
Interest expense   -    2,015 
Interest income   (70)   (496)
Net and comprehensive loss   1,649,136    3,198,607 
Weighted average number of shares outstanding   38,976,827    31,659,791 
Loss per share   0.04    0.10 

 

About VAL-083

VAL-083 is a “first-in-class”, small-molecule chemotherapeutic. In more than 40 Phase 1 and 2 clinical studies sponsored by the U.S. National Cancer Institutes, VAL-083 demonstrated safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and blood cancers. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas.

 

As a potential treatment for glioblastoma, VAL-083's mechanism of action appears to be unaffected by the expression of MGMT, a DNA repair enzyme that causes chemotherapy resistance to front-line treatment with Temodar® (temozolomide).

 

3
 

 

DelMar is currently studying multi-center VAL-083 in a Phase I/II clinical trial for patients with refractory glioblastoma multiforme in accordance with the protocol that has been filed with the U.S. Food and Drug Administration (FDA). Eligible GBM patients must have failed both Avastin® (bevacizumab) and Temodar® (temozolomide) unless either of these therapies was contraindicated. (ClinicalTrials.gov Identifier NCT01478178).

 

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc. was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

 

For further information, please visit http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989 follow us on Twitter @DelMarPharma or Facebook.com/delmarpharma. Investor Relations Counsel: Amato & Partners LLC.

 


Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

 

 

###

 

 

4
 


The following information was filed by Delmar Pharmaceuticals, Inc. (DMPI) on Friday, May 22, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Delmar Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Delmar Pharmaceuticals, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Log in with your credentials

or    

Forgot your details?

Create Account